Somatostatin receptor scintigraphy might be useful for detecting skeleton abnormalities in patients with multiple myeloma and plasmacytoma
Open Access
- 14 July 2009
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 37 (1) , 124-130
Abstract
Somatostatin receptor expression has been demonstrated on a number of plasma cell lines. Therefore, we questioned whether somatostatin receptor scintigraphy (SRS) can be used to demonstrate in vivo multiple myeloma (MM) activity.Keywords
This publication has 13 references indexed in Scilit:
- 18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple MyelomaJournal of Nuclear Medicine, 2008
- Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myelomaHaematologica, 2008
- Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trialHaematologica, 2007
- Technetium‐99m sestamibi scintigraphy is sensitive and specific for the staging and the follow‐up of patients with multiple myeloma: a multicentre study on 397 scansBritish Journal of Haematology, 2007
- Guidelines on the diagnosis and management of multiple myeloma 2005British Journal of Haematology, 2006
- The value of 99mTc-MIBI whole body scintigraphy in active and in remission multiple myeloma.2006
- Value of FDG PET in the Assessment of Patients with Multiple MyelomaAmerican Journal of Roentgenology, 2005
- Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II studyAnnals of Hematology, 2004
- Whole-body (18)F-FDG PET identifies high-risk myeloma.2002
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993